Last week I shared the first post from Peter Diamandis, M.D. into aging, longevity, and healthcare technologies that are converging to dramatically extend the healthy human lifespan, disrupting a soon-to-surpass $10 trillion healthcare system in the process.

I also mentioned I’ll be sharing some of the longevity busting protocols to address (slow down) a number of the mechanisms of aging that I currently use. These include the regular use of the peptide GDF11, periodic cyclical use of the peptide epitalon and the medication dasatinib combined with the flavonoids quercetin and fisetin, hormetic diet, physical activity and lifestyle challenges and proactive toxin removal.

The causes of aging are extremely complex and unclear.

But with longevity clinical trials increasing 3.5X, from 73 in 2012 to over 258 in 2019, more answers — and questions — are emerging than ever before.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

In this blog, Peter will cover two classes of emerging technologies:

How genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives. 

Genome Sequencing & Editing

Your genome is the software that runs your body.

A sequence of 3.2 billion letters makes you “you.” These base pairs of A’s, T’s, C’s, and G’s determine your hair color, your height, your personality, your propensity to disease, your lifespan, and so on.  Until recently, it's been very difficult to rapidly and cheaply "read" these letters — and even more difficult to understand what they mean.

Since 2001, the cost to sequence a whole human genome has plummeted exponentially, outpacing Moore's Law threefold. From an initial cost of $3.7 billion, it dropped to $10 million in 2006, and to $1,500 in 2015. 

Today, the cost of genome sequencing has dropped below $600, and according to Ilumina, the world’s leading sequencing company, the process will soon cost about $100 and take about an hour to complete. This represents one of the most powerful and transformative technology revolutions in healthcare.

• When we understand your genome, we'll be able to understand how to optimize "you." 

• We'll know the perfect foods, the perfect drugs, the perfect exercise regimen, and the perfect supplements, just for you. 

• We'll understand what microbiome types, or gut flora, are ideal for you (more on this in a later blog). 

• We’ll accurately predict how specific sedatives and medicines will impact you. 

• We’ll learn which diseases and illnesses you’re most likely to develop and, more importantly, how to best prevent them from developing in the first place (rather than trying to cure them after the fact).

CRISPR Gene Editing

In addition to reading the human genome, scientists can now edit a genome using a naturally occurring biological system discovered in 1987 called CRISPR/Cas9.  

Short for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9, the editing system was adapted from a naturally occurring defense system found in bacteria.

Here’s how it works:

The bacteria capture snippets of DNA from invading viruses (or bacteriophage) and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to "remember" the viruses (or closely related ones), and defend against future invasions.

If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses' DNA. The bacteria then use Cas9 to cut the DNA apart, which disables the virus. Most importantly, CRISPR is cheap, quick, easy to use, and more accurate than all previous gene editing methods.

As a result, CRISPR/Cas9 has swept through labs around the world as the way to edit a genome.  A short search in the literature will show an exponential rise in the number of CRISPR-related publications and patents.

PUBMED CRISPR MENTION COUNT

Figure: Number of CRISPR mentions on PubMed 2003-2017

2018 - Filled With CRISPR Breakthroughs

Early results are impressive. Researchers have used CRISPR to genetically engineer cocaine resistance into mice, reverse the gene defect causing Duchenne muscular dystrophy (DMD) in dogs, and reduce genetic deafness in mice.

Already this year, CRISPR-edited immune cells have been shown to successfully kill cancer cells in human patients. Researchers have discovered ways to activate CRISPR with light and use the gene-editing technology to better understand Alzheimer’s disease progression.

With great power comes great responsibility, and the opportunity for moral and ethical dilemmas.

In 2015, Chinese scientists sparked global controversy when they first edited human embryo cells in the lab with the goal of modifying genes that would make the child resistant to smallpox, HIV, and cholera. Three years later, in November 2018, researcher He Jiankui informed the world that the first set of CRISPR-engineered female twins had been delivered.

To accomplish his goal, Jiankui deleted a region of a receptor on the surface of white blood cells known as CCR5, introducing a rare, natural genetic variation that makes it more difficult for HIV to infect its favorite target, white blood cells. Because Jiankui forged ethical review documents and misled doctors in the process, he was sentenced to 3 years in prison and fined $429,000 last December. 

Coupled with significant ethical conversations necessary for progress, CRISPR will soon provide us the tools to eliminate diseases, create hardier offspring, produce new environmentally resistant crops, and even wipe out pathogens.

Senolytics, Nutraceuticals & Pharmaceuticals

Over the arc of your life, the cells in your body divide until they reach what is known as the Hayflick limit, or the number of times a normal human cell population will divide before cell division stops, which is typically about 50 divisions.

What normally follows next is programmed cell death or destruction by the immune system. A very small fraction of cells, however, become senescent cells and evade this fate to linger indefinitely. These lingering cells secrete a potent mix of molecules that triggers chronic inflammation, damages the surrounding tissue structures, and changes the behavior of nearby cells for the worse.

Senescent cells appear to be one of the root causes of aging, causing everything from fibrosis and blood vessel calcification to localized inflammatory conditions such as osteoarthritis to diminished lung function.

Fortunately, both the scientific and entrepreneurial communities have begun to work on senolytic therapies, moving the technology for selectively destroying senescent cells out of the laboratory and into a half-dozen startup companies.

Prominent companies in the field include the following:

1. Unity Biotechnology is developing senolytic medicines to selectively eliminate senescent cells with an initial focus on delivering localized therapy in osteoarthritis, ophthalmology, and pulmonary disease.

2. Oisin Biotechnologies is pioneering a programmable gene therapy that can destroy cells based on their internal biochemistry.

3. SIWA Therapeutics is working on an immunotherapy approach to the problem of senescent cells.

In recent years, researchers have identified or designed a handful of senolytic compounds that can curb aging by regulating senescent cells. Two of these drugs that have gained mainstay research traction are rapamycin and metformin.

To reduce senescent cell burden. In addition, I inject a small amount of the regenerative petide GDF11 two times weekly.

(1) Rapamycin 

Originally extracted from bacteria found on Easter Island, rapamycin acts on the m-TOR (mechanistic target of rapamycin) pathway to selectively block a key protein that facilitates cell division.

Currently, rapamycin derivatives are widely used as immunosuppression in organ and bone marrow transplants. Research now suggests that use results in prolonged lifespan, enhanced cognitive and immune function.

PureTech Health subsidiary resTORbio (which started 2018 by going public) is working on a rapamycin-based drug intended to enhance immunity and reduce infection. Their clinical-stage RTB101 drug works by inhibiting part of the mTOR pathway.

Results of the drug’s recent clinical trial include:

• Decreased incidence of infection

• Improved influenza vaccination response

• 30.6% decrease in respiratory tract infection

Impressive, to say the least.

(2) Metformin

Metformin is a widely used generic drug for mitigating liver sugar production in Type 2 diabetes patients. Researchers have found that Metformin also reduces oxidative stress and inflammation, which otherwise increase as we age. There is strong evidence that Metformin can augment cellular regeneration and dramatically mitigate cellular senescence by reducing both oxidative stress and inflammation.

Over 100 studies registered on ClinicalTrials.gov are currently following up on strong evidence of metformin’s protective effect against cancer.

(3) Nutraceuticals and NAD+

Beyond cellular senescence, certain critical nutrients and proteins tend to decline as a function of age. Nutraceuticals combat aging by supplementing and replenishing these declining nutrient levels. NAD+ exists in every cell, participating in every process from DNA repair to creating the energy vital for cellular processes. It’s been shown that NAD+ levels decline as we age.

The Elysium Health Basis supplement aims to elevate NAD+ levels in the body to extend one’s lifespan. Elysium’s first clinical study reports that Basis increases NAD+ levels consistently by a sustained 40 percent.

Figure: Results of Elysium's Clinical Study show that Basis increases NAD+ levels by a sustained 40%.

Conclusion

These are just a taste of the tremendous momentum that longevity and aging technology has right now.

As artificial intelligence and quantum computing transform how we decode our DNA and how we discover drugs, genetics and pharmaceuticals will become truly personalized.

The next blog in this series will demonstrate how artificial intelligence is converging with genetics and pharmaceuticals to transform how we approach longevity, aging and vitality.

We are edging closer toward a dramatically extended healthspan — where 100 is the new 60. What will you create, where will you explore, and how will you spend your time if you are able to add an additional 40 healthy years to your life?

Want more info from Peter?

Join FutureLoop

Over the past 2 years, Peter has built a machine-learning algorithm that scrapes the world’s news, science journals, and social feeds every day to understand how exponential technologies are impacting specific topics & industries. It’s called FutureLoop.

Last month, he launched "FutureLoop Pandemic Special Edition," a daily comprehensive update on the impact of exponential technologies (AI, Robotics, Drones, Cellular Medicine, CRISPR, Networks & Sensors) on the COVID-19 pandemic.

You can subscribe here. It’s free, fun + fast (20 seconds).